This Diabetes Drug Never Had a Chance

This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines and takes a look at two favorite health care focused dividend stocks. Market Checkup gives a full examination of the recent regulatory action around a new blood cancer drug, a European orphan drug approval, and why a big pharma shockingly stopped the Food and Drug Administration from reviewing its newest diabetes drug.

In this video, health-care analysts David Williamson and Max Macaluso discuss Sanofi's surprising decision to pull an experimental type 2 diabetes drug from the FDA approval process. Watch and find out the big pharma's reasoning behind the shocking decision, how this will impact sales of this drug if it is eventually approved, and its overall impact to Sanofi and its competitors.

Cash in on pharma stocks
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Follow David on Twitter: @MotleyDavid.

The article This Diabetes Drug Never Had a Chance originally appeared on Fool.com.

David Williamson owns shares of Eli Lilly. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.